Back to top
more

Biogen (BIIB)

(Real Time Quote from BATS)

$183.19 USD

183.19
269,856

-2.49 (-1.34%)

Updated Oct 7, 2024 01:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: BIIB, VRTX, ALXN Q1 Earnings Top & Other Pipeline Updates

by Zacks Equity Research

Key highlights of the past week are earnings releases by most leading biotech entities.

What's in the Cards for Sunesis (SNSS) This Earnings Season?

by Zacks Equity Research

Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.

Benjamin Rains headshot

3 Tech Stocks for Growth Investors to Buy Right Now

by Benjamin Rains

Let's check out three tech stocks that came through our screen today that growth investors might want to consider at the moment...

Alkermes (ALKS) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Alkermes (ALKS) reports narrower-than-expected loss and sales beat in the first quarter of 2019.

Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales

by Zacks Equity Research

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

Biogen (BIIB) Q1 Earnings & Sales Beat Estimates

by Zacks Equity Research

Biogen (BIIB) beat estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

What's in Store for Celgene Corporation (CELG) Q1 Earnings?

by Zacks Equity Research

Investors are looking forward to Revlimid's performance and updates on the impending acquisition agreement with Bristol-Myers, when Celgene Corporation (CELG) reports Q1 results.

Biogen (BIIB) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

While sales of Biogen's (BIIB) MS franchise are expected to decline in the first quarter of 2019 that of Spinraza are likely to increase.

Will Bristol-Myers (BMY) Disappoint This Earnings Season?

by Zacks Equity Research

Performance of Opdivo and the impending acquisition of Celgene Corporation will be key areas of focus for the investors, when Bristol-Myers (BMY) reports first-quarter results.

Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs

by Zacks Equity Research

Roche's (RHHBY) performance in the first quarter of 2019 is driven by solid strength of new drugs, which more than offset competition from biosimilars.

Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Biogen (BIIB) closed at $232.37 in the latest trading session, marking a -0.91% move from the prior day.

Biogen (BIIB) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Biogen (BIIB) closed the most recent trading day at $237.58, moving -0.9% from the previous trading session.

Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Celgene Gets Positive CHMP Nod for Revlimid Label Expansion

by Zacks Equity Research

Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.

Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval

by Zacks Equity Research

Merck KaaA (MKGAF) announces approval of Mavenclad in the United States as a treatment for multiple sclerosis. The drug is already approved in other countries including Europe.

4 Small Biotech Stocks Likely to Witness More Upside in 2019

by Zacks Equity Research

The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.

Novartis (NVS) Receives FDA Approval for MS Drug Mayzent

by Zacks Equity Research

Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.

Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

by Zacks Equity Research

Key highlights of the past week are multiple study failures and other pipeline updates.

Celgene (CELG) Submits NDA for MS Drug to FDA for Review

by Zacks Equity Research

Celgene (CELG) progresses with the development of its MS candidate, as it submits an application for the same to the FDA.

AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan

by Zacks Equity Research

AbbVie's (ABBV) psoriasis drug Skyrizi gains the maiden approval in Japan for treating adults with plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis.

Biogen Stock Crashes on Termination of Alzheimer's Studies

by Zacks Equity Research

Biogen (BIIB) and its Japanese partner, Eisai discontinue two late-stage studies evaluating aducanumab, in patients with Alzheimer's disease.

Company News For Mar 22, 2019

by Zacks Equity Research

Companies in the news are: BIIB, CAG, DRI, WSM

Mark Vickery headshot

Jobless Claims Dip, Philly Fed Swings, Biogen (BIIB) Plummets

by Mark Vickery

Jobless claims fell back to within the long-term range to 221K, Philly Fed surprised at 13.7 (after a negative February) and Biogen's phase 3 trial is halted.

Initial Jobless Claims Decline

by Zacks Equity Research

Initial Jobless Claims Decline